IDE196 (Darovasertib) in combination with Crizotinib versus the treatment chosen by the investigator as first-line therapy for HLA-A2 negative metastatic choroidal melanoma.

Critères de participation
1. Patients must be at least 18 years old. 2. This study is intended for patients with choroidal melanoma that has spread outside the eye and has not been previously treated with any other therapy (e.g., chemotherapy) and no local therapy (e.g., targeting the liver) for a disease that has spread outside the eye. 3. Prior therapy is allowed if it was administered to cure a localized disease (e.g., in the eye). (BASEC)

Critères d'exclusion
1. Prior treatment with a PKC inhibitor (including prior treatment with IDE196) or an inhibitor that directly targets MET or GNAQ/11. 2. Any other malignant disease not treated in this study. Exceptions to this exclusion criterion are: malignancies that have been treated curatively and have not recurred within 2 years prior to the study treatment; completely resected basal cell and squamous cell carcinomas of the skin; any malignancies considered indolent that have never required therapy; as well as any completely resected carcinoma in situ of any type. 3. An adverse event (AE) due to prior cancer therapy that has not resolved to ≤ grade 1, except for alopecia or anemia. • Any persistent diarrhea must be discussed with the sponsor's Medical Monitor. • Endocrinopathies resulting from prior immunotherapy are considered part of the medical history and not an AE. • A stable neuropathy of grade 2 is allowed. (BASEC)